"Plasma Phosphorylated Tau 217 Immunoassay: A Breakthrough in Early Alzheimer's Detection"
TL;DR
A cohort study evaluated the diagnostic accuracy of a commercially available plasma phosphorylated tau 217 (p-tau217) immunoassay for Alzheimer disease (AD) pathology. The study found that the p-tau217 immunoassay accurately identified abnormal amyloid β (Aβ) and tau pathologies, showing similar accuracies to cerebrospinal fluid biomarkers. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. The wider availability of high-performing assays may expedite the use of blood biomarkers in clinical settings and benefit the research community.
Topics:healthmedical-research#alzheimers-disease#biomarkers#cohort-study#diagnostic-accuracy#medical-research#plasma-p-tau217
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology JAMA Network
- New blood test that screens for Alzheimer’s may be a step closer to reality, study suggests CNN
- Alzheimer’s blood test could be used to screen even before symptoms: Study The Hill
- Groundbreaking Alzheimer's blood test can spot cruel disease 15 YEARS before symptoms emerge: Scientists belie Daily Mail
- Blood test boosts hopes of early Alzheimer's diagnosis Financial Times
Want the full story? Read the original reporting
Read on JAMA Network